Q BIOMED INC.: 10-Q filed 2022-11-03

Name: Q BIOMED INC.: 10-Q filed 2022-11-03
Creator: Q BIOMED INC.

What Q BIOMED INC. reported in its quarterly report filed 2022-11-03 (fiscal Q3 2022): 36 published measures, 106 facts as tagged in accession 0001410578-22-002927.

This filing

Form: 10-Q (quarterly report)
Filed: 2022-11-03
Fiscal period: fiscal Q3 2022
Accession: 0001410578-22-002927 on SEC EDGAR

Values are as tagged in this filing. A later filing can restate them; each measure links to its history page, which shows the latest-filed value per period. All Q BIOMED INC. filings.

Reported measures

Total assets

Resources recognized on the balance sheet. Book assets are not the market value of the business.

Period	Value	Unit	Days
At 2022-08-31	498,034	USD
At 2021-11-30	809,480	USD

Total liabilities

Recognized obligations at the reporting date. The definition and scope differ from interest-bearing debt.

Period	Value	Unit	Days
At 2022-08-31	7,732,350	USD
At 2021-11-30	5,494,842	USD

Stockholders equity

The reported residual interest after liabilities. It is an accounting amount, not market capitalization.

Period	Value	Unit
At 2022-08-31	-7,234,316	USD
At 2022-05-31	-7,091,031	USD
At 2021-11-30	-4,685,362	USD
At 2021-08-31	-2,996,479	USD
At 2021-05-31	-2,192,126	USD
At 2020-11-30	-1,075,481	USD

Net income or loss

Reported profit or loss for the period. Check the filing for attribution, exceptional items and discontinued operations before comparing companies.

Period	Value	Unit	Days
2022-06-01 to 2022-08-31	-795,112	USD	92
2021-12-01 to 2022-08-31	-4,354,564	USD	274
2021-06-01 to 2021-08-31	-1,787,392	USD	92
2020-12-01 to 2021-08-31	-6,170,676	USD	274

Operating cash flow

Cash generated or used by operating activities. Working-capital timing can make this differ substantially from reported income.

Period	Value	Unit	Days
2021-12-01 to 2022-08-31	-726,212	USD	274
2020-12-01 to 2021-08-31	-2,742,181	USD	274

Revenue

Revenue under this specific accounting concept. A missing value is not zero; filers can use other revenue concepts.

Period	Value	Unit	Days
2022-06-01 to 2022-08-31	26,271	USD	92
2021-12-01 to 2022-08-31	271,817	USD	274
2021-06-01 to 2021-08-31	45,675	USD	92
2020-12-01 to 2021-08-31	90,675	USD	274

Financing cash flow

Net cash from financing activities, including borrowing, repayments and transactions with owners. A positive amount does not establish operating profitability.

Period	Value	Unit	Days
2021-12-01 to 2022-08-31	520,030	USD	274
2020-12-01 to 2021-08-31	2,716,250	USD	274

Retained earnings or deficit

Accumulated undistributed earnings or deficit at the reporting date. This balance is not cash available for distribution.

Period	Value	Unit	Days
At 2022-08-31	-68,398,273	USD
At 2021-11-30	-64,126,618	USD

Basic weighted-average shares

Time-weighted shares used for basic earnings per share. This denominator differs from shares outstanding at a single reporting date.

Period	Value	Unit	Days
2022-06-01 to 2022-08-31	44,897,574	shares	92
2021-12-01 to 2022-08-31	35,878,092	shares	274
2021-06-01 to 2021-08-31	27,660,616	shares	92
2020-12-01 to 2021-08-31	26,207,685	shares	274

Diluted weighted-average shares

Weighted-average shares used for diluted earnings per share. Potential shares are included under the applicable dilution rules, not simply added to outstanding shares.

Period	Value	Unit	Days
2022-06-01 to 2022-08-31	44,897,574	shares	92
2021-12-01 to 2022-08-31	35,878,092	shares	274
2021-06-01 to 2021-08-31	27,660,616	shares	92
2020-12-01 to 2021-08-31	26,207,685	shares	274

Basic earnings per share

Reported earnings or loss per basic common share or unit. Inspect attribution, share classes and restatements before comparing periods. This is not a market return.

Period	Value	Unit	Days
2022-06-01 to 2022-08-31	-0.03	USD/shares	92
2021-12-01 to 2022-08-31	-0.16	USD/shares	274
2021-06-01 to 2021-08-31	-0.07	USD/shares	92
2020-12-01 to 2021-08-31	-0.25	USD/shares	274

Diluted earnings per share

Reported earnings or loss per share under dilution rules. Antidilutive instruments may be excluded. A diluted value can equal the basic value without implying no potential dilution.

Period	Value	Unit	Days
2022-06-01 to 2022-08-31	-0.03	USD/shares	92
2021-12-01 to 2022-08-31	-0.16	USD/shares	274
2021-06-01 to 2021-08-31	-0.07	USD/shares	92
2020-12-01 to 2021-08-31	-0.25	USD/shares	274

Share-based compensation expense

Reported noncash expense for share-based payment arrangements. Noncash treatment does not mean the awards have no economic cost to shareholders.

Period	Value	Unit	Days
2021-12-01 to 2022-08-31	327,707	USD	274
2020-12-01 to 2021-08-31	2,244,356	USD	274

Current assets

Assets classified as current under the normal operating cycle or one-year boundary. Not all current assets can be converted immediately into cash.

Period	Value	Unit	Days
At 2022-08-31	185,534	USD
At 2021-11-30	459,480	USD

Interest expense

Borrowing costs recognized as interest expense. This is distinct from cash interest paid and may not include every capitalized borrowing cost.

Period	Value	Unit	Days
2022-06-01 to 2022-08-31	239,638	USD	92
2021-12-01 to 2022-08-31	1,108,372	USD	274
2021-06-01 to 2021-08-31	99,418	USD	92
2020-12-01 to 2021-08-31	234,752	USD	274

Current liabilities

Obligations classified as current under the operating-cycle or one-year boundary. The balance includes more than short-term borrowing.

Period	Value	Unit	Days
At 2022-08-31	7,732,350	USD
At 2021-11-30	5,494,842	USD

Current accounts payable

Current amounts owed to suppliers for goods and services received. This is one component of current liabilities, not all accrued obligations.

Period	Value	Unit	Days
At 2022-08-31	2,079,652	USD
At 2021-11-30	1,345,319	USD

Net finite-lived intangible assets

Finite-lived intangible assets after amortization. This excludes goodwill and should not be combined with indefinite-lived intangible assets without checking scope.

Period	Value	Unit	Days
At 2022-08-31	312,500	USD
At 2021-11-30	350,000	USD

Net current accounts receivable

Current customer receivables after the allowance for credit loss. The balance is not cash collected or a guarantee of collection.

Period	Value	Unit	Days
At 2022-08-31	11,535	USD
At 2021-11-30	80,097	USD

Operating expenses

Recurring operating costs under this accounting concept, generally excluding production costs included in cost of sales. Check filing presentation before combining expense subtotals.

Period	Value	Unit	Days
2022-06-01 to 2022-08-31	740,914	USD	92
2021-12-01 to 2022-08-31	2,938,702	USD	274
2021-06-01 to 2021-08-31	1,573,844	USD	92
2020-12-01 to 2021-08-31	5,696,206	USD	274

Net inventory

Inventory carrying amount after applicable valuation and LIFO reserves. It does not establish realizable selling proceeds or inventory turnover without other inputs.

Period	Value	Unit	Days
At 2022-08-31	22,676	USD
At 2021-11-30	22,253	USD

Gross profit

Revenue less the costs directly attributed to the goods or services sold. It precedes other operating expenses and is not net income.

Period	Value	Unit	Days
2022-06-01 to 2022-08-31	-40,171	USD	92
2021-12-01 to 2022-08-31	58,679	USD	274
2021-06-01 to 2021-08-31	-28,095	USD	92
2020-12-01 to 2021-08-31	-70,088	USD	274

Cost of revenue

Costs attributed to goods produced and sold and services provided during the period. This is not the sum of every operating expense.

Period	Value	Unit	Days
2022-06-01 to 2022-08-31	66,442	USD	92
2021-12-01 to 2022-08-31	213,138	USD	274
2021-06-01 to 2021-08-31	73,770	USD	92
2020-12-01 to 2021-08-31	160,763	USD	274

Research and development expense

Research and development costs recognized as expense. Capitalization policies and acquired projects can make this differ from total cash invested in development.

Period	Value	Unit	Days
2022-06-01 to 2022-08-31	20,839	USD	92
2021-12-01 to 2022-08-31	103,159	USD	274
2021-06-01 to 2021-08-31	202,168	USD	92
2020-12-01 to 2021-08-31	667,538	USD	274

Common shares outstanding

Common shares outstanding at the reporting date. This point-in-time count differs from the weighted-average shares used for earnings per share and can exclude other share classes.

Period	Value	Unit	Days
At 2022-08-31	57,364,746	shares
At 2021-11-30	28,647,788	shares

Cash including restricted cash

Cash, cash equivalents and restricted cash as reported in the cash flow reconciliation. Restricted amounts are not freely available, so this is not the same as unrestricted cash.

Period	Value	Unit
At 2022-08-31	137,827	USD
At 2021-11-30	344,009	USD
At 2021-08-31	151,214	USD
At 2020-11-30	177,145	USD

Additional paid-in capital

Capital contributed above par value under this concept. It records historical contributions, not the current value of the equity or cash on hand.

Period	Value	Unit	Days
At 2022-08-31	55,851,395	USD
At 2021-11-30	53,335,901	USD

Accrued current liabilities

Current obligations accrued for goods and services received but not yet invoiced or paid. This is one component of current liabilities, not all short-term obligations.

Period	Value	Unit	Days
At 2022-08-31	1,216,374	USD
At 2021-11-30	954,309	USD

Prepaid expenses and other current assets

Prepayments and other current assets grouped under this concept. The balance is not cash and its composition differs by filer.

Period	Value	Unit	Days
At 2022-08-31	13,496	USD
At 2021-11-30	13,121	USD

Pre-tax income or loss from continuing operations

Income or loss from continuing operations before income taxes and noncontrolling interests. It excludes discontinued operations and is not net income.

Period	Value	Unit	Days
2022-06-01 to 2022-08-31	-781,085	USD	92
2021-12-01 to 2022-08-31	-2,880,023	USD	274
2021-06-01 to 2021-08-31	-1,601,939	USD	92
2020-12-01 to 2021-08-31	-5,766,294	USD	274

Net income available to common stockholders

Net income after preferred dividends and similar adjustments, the numerator for basic earnings per share. It can be lower than reported net income.

Period	Value	Unit	Days
2022-06-01 to 2022-08-31	-1,369,602	USD	92
2021-12-01 to 2022-08-31	-5,687,013	USD	274
2021-06-01 to 2021-08-31	-1,912,877	USD	92
2020-12-01 to 2021-08-31	-6,546,193	USD	274

General and administrative expense

General and administrative costs reported under this concept, separate from selling expense. Filers group overhead differently, so compare presentation before comparing companies.

Period	Value	Unit	Days
2022-06-01 to 2022-08-31	720,075	USD	92
2021-12-01 to 2022-08-31	2,835,543	USD	274
2021-06-01 to 2021-08-31	1,371,676	USD	92
2020-12-01 to 2021-08-31	5,028,668	USD	274

Interest paid, net

Cash interest paid during the period, net of amounts capitalized where the filer reports it that way. It differs from interest expense recognized.

Period	Value	Unit	Days
2021-12-01 to 2022-08-31	0	USD	274
2020-12-01 to 2021-08-31	441	USD	274

Income taxes paid, net

Cash income taxes paid net of refunds during the period. It differs from income tax expense and can reflect prior years and estimated payments.

Period	Value	Unit	Days
2021-12-01 to 2022-08-31	0	USD	274
2020-12-01 to 2021-08-31	0	USD	274

Change in accounts receivable

The cash flow adjustment for the change in receivables during the period. A positive value under this concept means receivables grew and reduced operating cash flow.

Period	Value	Unit	Days
2021-12-01 to 2022-08-31	-68,562	USD	274
2020-12-01 to 2021-08-31	38,875	USD	274

Change in accounts payable

The cash flow adjustment for the change in payables during the period. A positive value under this concept means payables grew and added to operating cash flow.

Period	Value	Unit	Days
2021-12-01 to 2022-08-31	1,264,641	USD	274
2020-12-01 to 2021-08-31	851,332	USD	274

Inspect the source

Entity: Q BIOMED INC. / CIK 0001596062
Captured: 2026-09-22 19:53 UTC
SEC response SHA-256: f89c4e51720d8de34ddffc303f833ea01697bd4742662935a9f3cf09e3e7efbc

Current SEC company facts · Download the original response snapshot (gzip) · Download the selected JSON

Every published concept a filing tagged, with the periods it covered, as reported in that filing at capture time. Forms 10-K, 10-K/A, 10-Q, 10-Q/A, 20-F, 20-F/A, 40-F, 40-F/A. A filing page needs at least 8 published concepts. Later filings can restate these values; the company history pages show the latest-filed value per period.

Public company accounting reference, not market prices, returns, an investment recommendation, or ALPHAC performance. Validate a separately constructed return series with the validation API; accounting values are not returns.

Use this in research

A financial period ends before its results become public. Use the filing date as a minimum availability boundary, inspect amendments, and retain the original filing vintage when testing historical signals. This latest-filed selection can contain information unavailable at the time.

These pages do not supply prices, total-return histories, corporate-action adjustments or a tradable universe. Build those inputs separately before evaluating a strategy. A profitable backtest can still reflect selection bias or costs that were left out.

Research methodology · Execution and cost assumptions · Check backtest overfitting

Build with the open-source tools

Use these accounting records as inspectable inputs. When you have constructed a return series, the validation tools can help test its statistical evidence and preserve the result with its limitations.

Read the published dataset with Python

import json
from urllib.request import urlopen

with urlopen("https://canlicapital.com/company-data/0001596062.json") as response:
    record = json.load(response)
print(record["fetched_at"])
print(record["policy"])
for concept in record["concepts"]:
    print(concept["tag"], next(iter(concept["observations"])))